Monoclonal gammopathy of undetermined significance in atomic bomb survivors: Incidence and transformation to multiple myeloma

British Journal of Haematology

Volumn 121, Issue 3, 2003, Pages 405-410

  Neriishi, Kazuo ^a   Nakashima, Eiji ^a   Suzuki, Gen ^a  

^a RADIATION EFFECTS RESEARCH FOUNDATION   (Japan)

Author keywords

A bomb survivors; MGUS; Multiple myeloma; Radiation

Indexed keywords

ARTICLE; ATOMIC BOMB SURVIVOR; CANCER MORTALITY; CANCER RISK; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HUMAN; INCIDENCE; JAPAN; MAJOR CLINICAL STUDY; MALE; MALIGNANT TRANSFORMATION; MONOCLONAL IMMUNOGLOBULINEMIA; MULTIPLE MYELOMA; ONSET AGE; POPULATION DYNAMICS; PRIORITY JOURNAL; RADIATION DOSE; RADIATION EXPOSURE; RISK; STATISTICAL SIGNIFICANCE;

AGE OF ONSET; AGED; AGED, 80 AND OVER; DISEASE PROGRESSION; FEMALE; HUMANS; INCIDENCE; JAPAN; MALE; MIDDLE AGED; MONOCLONAL GAMMOPATHIES, BENIGN; MULTIPLE MYELOMA; NEOPLASMS, RADIATION-INDUCED; NUCLEAR WARFARE; RADIATION DOSAGE; SURVIVORS;

EID: 0038015894     PISSN: 00071048     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2141.2003.04287.x     Document Type: Article

References (34)

1. Bataille, R., Jourdan, M., Zhang, X.G. & Klein, B. (1989) Serum levels of interleukin 6, a potent myeloma cell growth factor, as a reflect of disease severity in plasma cell dyscrasias. Journal of Clinical Investigation, 84, 2008-2011.
2. Bergsagel, D. (1995) The incidence and epidemiology of plasma cell neoplasms. Stem Cells, 13, 1-9.
3. Blade, J., Lopez-Guillermo, A., Rozman, C., Cervantes, F., Salgado, C., Aguilar, J.L., Vives-Corrons, J.L. & Montserrat, E. (1992) Malignant transformation and life expectancy in monoclonal gammopathy of undetermined significance. British Journal of Haematology, 81, 391-394.
4. Colls, B.M. (1999) Monoclonal gammopathy of undetermined significance (MGUS): 31 year follow up of a community study. Australian and New Zealand Journal of Medicine, 29, 500-504.
5. Cuzick, J. (1981) Radiation-induced myelomatosis. New England Journal of Medicine, 304, 204-210.
6. Davies, F.E., Rollinson, S.J., Rawstron, A.C., Roman, E., Richards, S., Drayson, M., Child, J.A. & Morgan, G.J. (2000) High-producer haplotypes of tumor necrosis factor alpha and lymphotoxin alpha are associated with an increased risk of myeloma and have an improved progression-free survival after treatment. Journal of Clinical Oncology, 18, 2843-2851.
7. Gilbert, E.S. & Marks, S. (1979) An analysis of the mortality of workers in a nuclear facility. Radiation Research, 79, 122-148.
8. Gilbert, E.S., Omohundro, E., Buchanan, J.A. & Holter, N.A. (1993) Mortality of workers at the Hanford site: 1945-86. Health Physics, 64, 577-590.
9. Gregersen, H., Madsen, K.M., Sorensen, H.T., Schonheyder, H.C., Ibsen, J.S. & Dahlerup, J.F. (1998) The risk of bacteremia in patients with monoclonal gammopathy of undetermined significance. European Journal of Haematology, 61, 140-144.
10. Gregersen, H., Ibsen, J., Mellemkjoer, L., Dahlerup, J., Olsen, J. & Sorensen, H. (2001) Mortality and causes of death in patients with monoclonal gammopathy of undetermined significance. British Journal of Haematology, 112, 353-357.
11. Hayashi, T., Kusunoki, Y., Hakoda, M., Morishita, Y., Kubo, Y., Maki, M., Kasagi, F., Kodama, K., MacPhee, D.G. & Kyoizumi, S. (2002) Radiation dose-dependent increases in inflammatory response markers in atomic bomb survivors. RERF MS 2-02.
12. Huntington, G.B., McHahon, B., Jablon, S. & Land, C.E. (1979) Review of report by Mancuso, Stewart, and Kneale of radiation exposure of Hanford workers. Health Physics, 37, 207-220.
13. Ichimaru, M., Ishimaru, T., Mikami, M. & Matsunaga, M. (1982) Multiple myeloma among atomic bomb survivors in Hiroshima and Nagasaki by marrow dose. 1950-76. Journal of the National Cancer Institute, 69, 323-328.
14. Kanoh, T., Yago, K. & Okuma, M. (1990) A long-term observation of development from monoclonal gammopathy of undetermined significance (MGUS) into primary amyloidosis. Rinsho Ketsueki, 31, 1740-1744.
15. Kawano, M., Hirano, T. & Matsuda, T. (1988) Autocrine generation and requirement of BSF/IL-6 for human multiple myeloma. Nature, 332, 83-85.
16. Kissel, J.T. & Mendell, J.R. (1996) Neuropathies associated with monoclonal gammopathies. Neuromuscular Disorders, 6, 3-18.
17. Klein, B., Zhang, X.Z., Lu, Z.Y. & Bataille, R. (1995) IL-6 in human multiple myeloma. Blood, 85, 863-872.
18. Kyle, R.A., Therneau, T.M., Rajkumar, S.V., Offord, J.R., Larson, D.R., Plevak, M.F. & Melton, III, L.J. (2002) A long-term study of prognosis in monoclonal gammopathy of undetermined significance. New England Journal of Medicine, 346, 564-569.
19. Lolin, Y.I., Chow, J. & Wickham, N.W. (1996) Monoclonal gammopathy of unknown significance and malignant paraproteinemia in Hong Kong. American Journal of Clinical Pathology, 106, 449-456.
20. Lust, J.A. & Donovan, K.A. (1999) The role of interleukin-1 beta in the pathogenesis of multiple myeloma. Hematology/Oncology Clinics of North America, 13, 1117-1125.
21. Mancuso, T.F., Stewart, A. & Kneal, G. (1977) Radiation exposure of Hanford workers dying from cancer and other causes. Health Physics, 33, 369-385.
22. Neriishi, K., Yoshimoto, Y., Carter, R.L., Matsuo, T., Ichimaru, M., Mikami, M., Abe, T., Fujimura, K. & Kuramoto, A. (1993) Monoclonal gammopathy in atomic bomb survivors. Radiation Research, 133, 351-359.
23. Neriishi, K., Nakashima, E. & Delongchamp, R.R. (2001) Persistent subclinical inflammation among atomic-bomb survivors. International Journal of Radiation Biology, 77, 475-482.
24. Ogmundsdottir, H.M., Haraldsdottir, V.M., Johannesson, G., Olafsdottir, G., Bjarnadottir, K., Sigvaldason, H. & Tulinius, H. (2002) Monoclonal gammopathy in Iceland: a population-based registry and follow-up. British Journal of Haematology, 118, 166-173.
25. Ong, F., Hermans, J., Noordijk, E.M., Wijermans, P.W., Seelen, P.J., de Kieviet, W., Gerrits, W.B., Kluin, P.M. & Kluin-Nelemans, J.C. (1997) A population-based registry on paraproteinaemia in the Netherlands. Comprehensive Cancer Centre West, Leiden, the Netherlands. British Journal of Haematology. 99, 914-920.
26. Pasqualetti, P., Collacciani, A. & Casale, R. (1996) Risk of monoclonal gammopathy of undetermined significance: a case-referent study. American Journal of Hematology, 52, 217-220.
27. Pelliniemi, T.T., Irjala, K., Mattila, K., Pulkki, K., Rajamaki, A., Tienhaara, A., Laakso, M. & Lahtinen, R. (1995) Immunoreactive interleukin-6 and acute phase proteins as prognostic factors in multiple myeloma. Finnish Leukemia Group. Blood, 85, 765-767.
28. Pierce, D.A., Shimizu, Y., Preston, D.L., Vaeth, M. & Mabuchi, K. (1996) Studies of the mortality of atomic bomb survivors. Report 12, Part I. Cancer: 1950-90. Radiation Research, 146, 1-27.
29. van de Poel, M.H., Coebergh, J.W. & Hillen, H.F. (1995) Malignant transformation of monoclonal gammopathy of undetermined significance among out-patients of a community hospital in southeastern Netherlands. British Journal of Haematology, 91, 121-125.
30. Preston, D.L., Kusumi, S., Tomonaga, M., Izumi, S., Ron, E., Kuramoto, A., Kamada, N., Dohy, H., Matsuo, T., Nonaka, H., Thompson, D.E., Soda, M. & Mabuchi, K. (1994) Cancer incidence in atomic bomb survivors. Part III: leukemia, lymphoma and multiple myeloma, 1950-87. Radiation Research, 137s, 68-97.
31. Roesch, W.C. (ed.) (1987) US-Japan Joint Reassessment of Atomic Bomb Radiation Dosimetry in Hiroshima and Nagasaki, Final Report Vol. 1. Radiation Effects Research Foundation, Hiroshima.
32. Schaar, C.G., Kaiser, U., Snijder, S., Ong, F., Hermans, J., Franck, P.F. & Kluin-Nelemans, J.C. (1999) Serum interleukin-6 has no discriminatory role in paraproteinaemia nor a prognostic role in multiple myeloma. British Journal of Haematology, 107, 132-138.
33. Vallat, J.M., Jauberteau, M.O., Bordessoule, D., Yardin, C., Preux, P.M. & Couratier, P. (1996) Link between peripheral neuropathy and monoclonal dysglobulinemia: a study of 66 cases. Journal of Neurological Sciences, 137, 124-130.
34. Vuckovic, J., Ilic, A., Knezevic, N., Marinkovic, M., Zemunik, T. & Dubravcic, M. (1997) Prognosis in monoclonal gammopathy of undetermined significance. British Journal of Haematology, 97, 649-651.